Manulife stock price forecast sell-side consensus elevates Manulife

Sell-side consensus elevates Manulife stock price forecast on increased premium margins and cost optimization, pushing long-term profit estimates upward. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Sun Life’s recent earnings painted a more challenging picture. The insurer’s shares dipped by approximately 9% following a quarterly profit that fell short of analysts’ expectations. The Canadian stock’s U.S. segment, which contributes about 20% to its earnings, faced higher claims related to severe medical conditions, particularly in its medical stop-loss insurance. This surge in claims has been partly attributed to delayed medical check-ups during the pandemic, leading to more severe health issues. In response, Sun Life plans to implement a 2% increase in insurance prices to mitigate these challenges. Recent trading patterns in Manulife stock price forecast suggest resistance near CAD 29.20, with institutional buying signaling confidence in long-term earnings stability despite short-term volatility in global equities.